Horizon Oncology Research,

Lafayette, Indiana 47905

0 studies enrolling now · 11 studies all time

What they study most

Acute Myeloid Leukemia, Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer, Advanced Metastatic Castration-Resistant Prostate Cancer, Advanced Platinum-Resistant Ovarian Cancer, Advanced Triple Negative Breast Cancer, Bladder Cancer, Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme, Malignancy, Melanoma, Multiple Myeloma

Studies at this site

• Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors — Recruiting now
• A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer — Completed
• A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors — Stopped early
• A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors — Stopped early
• A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies — Completed
• A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer — Completed
• Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma — Completed
• BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma — Completed
• A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT — Stopped early
• A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects — Completed
• Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies — Status unconfirmed